UNSPSC 51171823: Granisetron

This classification denotes a 5-ht3 receptor antagonist with the molecular formula C18H24N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WZG3J2MCOL, chemically known as 1h-indazole-3-carboxamide, 1-methyl-n-(9-methyl-9-azabicyclo(3.3.1)non-3-yl)-, endo- but generally known as granisetron, which bears US NIH Compound Identifier 3510. European Medicines Agency schedules Granisetron in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07964MIG.

UNSPSC 51171823 Granisetron, a Commodity code, encompasses antiemetic pharmaceutical products state and local governments procure through cooperative purchasing mechanisms, direct-to-manufacturer initiatives, and county-level clinical and correctional health programs. The recent solicitation activity shows state and local buyers acquiring granisetron and similar generic antiemetics as part of broader pharmaceutical supply contracts, generic drug cooperative agreements, and specialized clinical testing and treatment services. State and local issuing bodies under this code include state health and human services commissions, county correctional and community supervision departments, multistate cooperative purchasing alliances, and state procurement offices. The work involves sourcing, pricing, and delivery of pharmaceutical products through authorized wholesalers and direct manufacturer channels, often with requirements for cGMP certification, FDA compliance, and compliance with drug supply chain security regulations.

Activity concentrates in Texas and Minnesota, with the Texas Health and Human Services Commission pursuing a Therapeutic Pharmacy Initiative to establish direct-to-manufacturer prescription relationships, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administering multistate generic pharmaceutical contracts across participating state and local government facilities including Oregon. The Collin County Community Supervision and Corrections Department in Texas issued RFP 2026-327 on July 9, 2026 for offender specimen collection and drug testing services (due July 23, 2026), valued at $600,000 over two years with three optional one-year renewals, requiring vendor capacity for approximately 25,031 annual drug screening and confirmation tests. The MMCAP RFP (S1070000015802), posted January 20, 2026 with proposals due March 26, 2026, sought generic multi-source pharmaceuticals and OTC products from manufacturers for distribution through three authorized wholesalers, with contract effectiveness July 1, 2026 for a two-year initial term. The Texas HHS Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on vendors' capacity to establish direct contracts with self-insured employer and state agency plans outside traditional pharmacy benefit manager and group purchasing organization channels, signaling potential future procurement activity in direct-to-manufacturer pharmaceutical sourcing.